Abstract
Cancer is currently the first or second most common contributor to premature mortality in most countries of the world. The global number of patients with cancer is expected to rise over the next 50 years owing to the strong influence of demographic changes, such as population ageing and growth, on the diverging trends in cancer incidence in different regions. Assuming that the latest incidence trends continue for the major cancer types, we predict a doubling of the incidence of all cancers combined by 2070 relative to 2020. The greatest increases are predicted in lower-resource settings, in countries currently assigned a low Human Development Index (HDI), whereas the predicted increases in national burden diminish with increasing levels of national HDI. Herein, we assess studies modelling the future burden of cancer that underscore how comprehensive cancer prevention strategies can markedly reduce the prevalence of major risk factors and, in so doing, the number of future cancer cases. Focusing on an in-depth assessment of prevention strategies that target tobacco smoking, overweight and obesity, and human papillomavirus infection, we discuss how stepwise, population-level approaches with amenable goals can avert millions of future cancer diagnoses worldwide. In the absence of a step-change in cancer prevention delivery, tobacco smoking will remain the leading preventable cause of cancer, and overweight and obesity might well present a comparable opportunity for prevention, given its increasing prevalence globally in the past few decades. Countries must therefore instigate national cancer control programmes aimed at preventing cancer, and with some urgency, if such programmes are to yield the desired public health and economic benefits in this century.
© 2021. Springer Nature Limited.
Similar articles
-
Lancet Oncol. 2012 Aug;13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5. Epub 2012 Jun 1.PMID: 22658655
-
Lancet Oncol. 2019 Mar;20(3):394-407. doi: 10.1016/S1470-2045(18)30836-2. Epub 2019 Feb 19.PMID: 30795950
-
Lancet. 2018 Nov 10;392(10159):2052-2090. doi: 10.1016/S0140-6736(18)31694-5. Epub 2018 Oct 16.PMID: 30340847 Free PMC article.
-
In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11.PMID: 30212088 Free Books & Documents. Review.
-
[Cancer and demographic transition].
Vopr Onkol. 2004;50(2):127-44.PMID: 15176213 Review. Russian.
Cited by
-
Sci Rep. 2024 Jul 9;14(1):15805. doi: 10.1038/s41598-024-66141-7.PMID: 38982173 Free PMC article.
-
An Overview of Antitumour Activity of Polysaccharides.
Molecules. 2022 Nov 21;27(22):8083. doi: 10.3390/molecules27228083.PMID: 36432183 Free PMC article. Review. -
Targeting the (pro)renin receptor in cancers: from signaling to pathophysiological effects.
J Cancer Res Clin Oncol. 2023 Jun;149(6):2595-2605. doi: 10.1007/s00432-022-04373-8. Epub 2022 Sep 25.PMID: 36153775 Review. -
Hydrodynamic Cavitation on a Chip: A Tool to Detect Circulating Tumor Cells.
ACS Appl Mater Interfaces. 2022 Sep 14;14(36):40688-40697. doi: 10.1021/acsami.2c12356. Epub 2022 Sep 1.PMID: 36048001 Free PMC article. -
CISD3 is a prognostic biomarker and therapeutic target in pan-cancer.
Sci Rep. 2024 Oct 8;14(1):23494. doi: 10.1038/s41598-024-74247-1.PMID: 39379442 Free PMC article.
References
-
- Cao, B., Bray, F., Ilbawi, A. & Soerjomataram, I. Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target. Lancet Glob. Health 6, e1288–e1296 (2018). – PubMed – DOI – PMC
- Bray, F., Jemal, A., Grey, N., Ferlay, J. & Forman, D. Global cancer transitions according to the Human Development Index (2008−2030): a population-based study. Lancet Oncol. 13, 790–801 (2012). – PubMed – DOI – PMC
- World Health Organization. WHO report on cancer: setting priorities, investing wisely and providing care for all (WHO, 2020).


